Home/Allegro Ophthalmics/Stephanie Yee

SY

Stephanie Yee

Vice President, Finance

Allegro Ophthalmics

Therapeutic Areas

Ophthalmology Retinal Diseases Dry Eye Syndromes

Allegro Ophthalmics Pipeline

Drug	Indication	Phase
Risuteganib (Luminate®)	Intermediate Dry Age-Related Macular Degeneration (AMD)	Phase 2b/3
ALG-1007	Dry Eye Disease (DED)	Pre-clinical/Phase 1

Leadership Team at Allegro Ophthalmics

Vicken Karageozian, MD

Co-Founder, President and Chief Executive Officer

Hampar Karageozian, MSc, MBA

Co-Founder, Chief Technology Officer and Chairman Emeritus

Melvin Sarayba, MD

Vice President of Clinical Affairs

View full Allegro Ophthalmics profile